Dr. Ischiropoulos's research objectives are to develop and test novel therapeutics for long-chain fatty acid oxidation (LCFA) disorders, a collection of inherited metabolic diseases that affect the heart, liver and muscle. A second area of interest is the resolution of the nitric oxide signaling pathways at the proteome level in the cardiovascular and neuronal systems.
Dr. Eichenwald's research interests include clinical trials and quality improvement in neonatal-perinatal medicine. He has extensive experience in the conduct of multicenter clinical trials, having served as a site principal investigator for several funded, multicenter randomized trials of interventions aimed at improving outcomes of premature newborns.
Physician-researchers from the Cardiac Center at Children’s Hospital of Philadelphia (CHOP) presented new findings on pediatric cardiovascular disease at the American College of Cardiology’s 67th Annual Scientific Session & Expo 2018 in Orlando, Fla.
What one researcher describes as asthma, another might call reactive airway disease. Unfortunately, such examples demonstrate the lack of a common pediatric research terminology, which presents a barrier to data reuse, sharing, and integration.
The research objectives of the Ischiropoulos Lab are to elucidate the nitric oxide signaling pathways at the proteome level in the cardiovascular and neuronal systems; define the molecular mechanisms by which nitric oxide signaling regulates metabolic pathways during development and aging; and develop and test novel therapeutics for long-chain fatty acid oxidation disorders.